[go: up one dir, main page]

NO20075155L - Fremgangsmater for behandling av medikamentmisbruk og -avhengighet. - Google Patents

Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.

Info

Publication number
NO20075155L
NO20075155L NO20075155A NO20075155A NO20075155L NO 20075155 L NO20075155 L NO 20075155L NO 20075155 A NO20075155 A NO 20075155A NO 20075155 A NO20075155 A NO 20075155A NO 20075155 L NO20075155 L NO 20075155L
Authority
NO
Norway
Prior art keywords
methods
addiction
compositions
treating
drug abuse
Prior art date
Application number
NO20075155A
Other languages
English (en)
Inventor
Sanjay Sabnani
Donald Wesson
Josseph Dunn
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of NO20075155L publication Critical patent/NO20075155L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives fremgangsmåter og blandinger for behandling og lindring av symptomer og sykdom forbundet med indikasjoner forårsaket av en fysiologisk drivkraft til å lindre en følelse av angst. Nærmere bestemt beskrives fremgangsmåter og blandinger for behandling og lindring av symptomer forbundet med stoffmisbruk og abstinens. Det beskrives fremgangsmåter og blandinger for behandling og lindring av symptomer forbundet med addiksjon til antidepressiva, opiater, nikotin eller marihuana. Etter en fremgangsmåte behandles en pasient med en blanding som direkte eller indirekte modulerer GABAA ved å modulere ekspresjonen av GABAA reseptor (4-subenheten.
NO20075155A 2005-04-07 2007-10-10 Fremgangsmater for behandling av medikamentmisbruk og -avhengighet. NO20075155L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US72901305P 2005-10-21 2005-10-21
US72897905P 2005-10-21 2005-10-21
PCT/US2006/013099 WO2006110557A2 (en) 2005-04-07 2006-04-07 Methods for the treatment of substance abuse and dependence

Publications (1)

Publication Number Publication Date
NO20075155L true NO20075155L (no) 2008-01-07

Family

ID=37087555

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20075161A NO20075161L (no) 2005-04-07 2007-10-10 Fremgangsmate for behandling av angstrelaterte lidelser
NO20075155A NO20075155L (no) 2005-04-07 2007-10-10 Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20075161A NO20075161L (no) 2005-04-07 2007-10-10 Fremgangsmate for behandling av angstrelaterte lidelser

Country Status (12)

Country Link
US (3) US20080207601A1 (no)
EP (3) EP1868593A2 (no)
JP (3) JP2008538748A (no)
KR (2) KR20080004580A (no)
AU (3) AU2006235318A1 (no)
BR (2) BRPI0609744A2 (no)
CA (3) CA2604887A1 (no)
CR (2) CR9410A (no)
IL (2) IL186447A0 (no)
MX (2) MX2007012353A (no)
NO (2) NO20075161L (no)
WO (3) WO2006110642A2 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
EP2164324B1 (en) 2007-06-15 2014-08-13 University Of Florida Research Foundation Therapeutic compounds
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
AU2010215075B2 (en) * 2009-02-20 2015-08-20 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20120295893A1 (en) * 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
US8202525B2 (en) 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20160120877A1 (en) * 2010-07-16 2016-05-05 James S Rowe Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
KR102400891B1 (ko) * 2012-12-18 2022-05-20 워싱톤 유니버시티 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10266534B2 (en) * 2014-06-26 2019-04-23 The Johns Hopkins University Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
AU2017229656B2 (en) 2016-03-08 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
DK3565528T3 (da) * 2017-01-09 2025-05-26 Relmada Therapeutics Inc Injicerbare suspensioner
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
US20200101066A1 (en) * 2017-03-28 2020-04-02 LDN Pharma Limited Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
CA3076193A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit symptoms associated with opioid withdrawal
WO2019055942A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE
US12414956B2 (en) 2017-09-20 2025-09-16 Calista Capital, Llc Method for smoking cessation
US10966988B2 (en) * 2017-09-20 2021-04-06 Calista Capital, Llc Method for smoking cessation
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
CA3094026A1 (en) * 2018-04-05 2019-10-10 Asarina Pharma Aps Gaba-a antagonists for treating substance withdrawal disorders
AU2019249277A1 (en) * 2018-04-06 2020-10-22 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
EP3937947A4 (en) * 2019-03-14 2022-11-16 Palmaya Pty Ltd TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM
JP7638967B2 (ja) * 2019-08-26 2025-03-04 ピリオド ピル ベーフェー 月経周期性症状の治療
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
CA3201498A1 (en) * 2020-11-27 2022-06-02 Trexapharm Pty Ltd Compositions comprising flumazenil and naltrexone and methods for use thereof
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
IL134651A0 (en) * 1997-08-28 2001-04-30 Janus Pharmaceuticals Inc Pharmaceutical compositions containing an anti-androgen
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
WO2001015687A1 (en) * 1999-08-27 2001-03-08 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
IL156798A0 (en) * 2001-01-17 2004-02-08 Hythiam Inc Use of flumazenil in developing a drug for the treatment of alcohol dependency
DK1378267T3 (da) * 2001-02-15 2007-10-08 Hythiam Inc Anvendelse af flumazenil til fremstilling af et medikament til behandling af kokainafhængighed
GB0311859D0 (en) * 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
EP2343073A3 (en) * 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
BRPI0610693A2 (pt) 2016-11-22
WO2006110557A2 (en) 2006-10-19
CA2604887A1 (en) 2006-10-19
EP1868593A2 (en) 2007-12-26
MX2007012355A (es) 2008-01-16
EP1901727A4 (en) 2009-11-11
WO2006110557A3 (en) 2009-04-16
KR20080004580A (ko) 2008-01-09
WO2006110642A3 (en) 2009-04-23
US20080207601A1 (en) 2008-08-28
EP1901727A2 (en) 2008-03-26
EP1868432A2 (en) 2007-12-26
CA2603519A1 (en) 2006-10-19
AU2006235234A1 (en) 2006-10-19
US8012958B2 (en) 2011-09-06
CA2603533A1 (en) 2006-10-19
BRPI0609744A2 (pt) 2010-04-27
JP2008538748A (ja) 2008-11-06
CR9413A (es) 2008-01-21
NO20075161L (no) 2008-01-07
US20080280885A1 (en) 2008-11-13
WO2006110580A2 (en) 2006-10-19
AU2006235318A1 (en) 2006-10-19
AU2006235257A1 (en) 2006-10-19
WO2006110580A3 (en) 2007-08-16
JP2008535852A (ja) 2008-09-04
KR20080004581A (ko) 2008-01-09
US20080255097A1 (en) 2008-10-16
EP1868432A4 (en) 2009-11-04
AU2006235257B2 (en) 2010-11-04
MX2007012353A (es) 2008-01-16
JP2008535850A (ja) 2008-09-04
CR9410A (es) 2008-02-21
IL186450A0 (en) 2008-01-20
IL186447A0 (en) 2008-08-07
WO2006110642A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
NO20075155L (no) Fremgangsmater for behandling av medikamentmisbruk og -avhengighet.
NO20053041L (no) Behandling av diabetes.
Kasper et al. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action
Seifi et al. The effect of lavender essential oil on anxiety level in patients undergoing coronary artery bypass graft surgery: A double-blinded randomized clinical trial
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
Makhlouf et al. Depression and erectile dysfunction
NO20074117L (no) Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstander
WO2006023703A3 (en) Method for treating sleep related breathing disorders
WO2007143607A3 (en) Method of treating atrophic vaginitis
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
Chen et al. Electroacupuncture reduces postoperative pain and analgesic consumption in patients undergoing thoracic surgery: a randomized study
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
BRPI0513840A (pt) método para controle de obesidade em um paciente mamìfero necessitado de um tal tratamento, método para tratamento de obesidade em um paciente humano diabético e sendo tratado com uma droga receitada para diabetes, método para tratamento de diabetes mellitus em um paciente mamìfero necessitado de um tal tratamento para controle da diabetes mellitus, método para tratamento ou controle de hiperglicemia em um paciente mamìfero necessitado de um tal tratamento, composição para uso no tratamento de obesidade, diabetes, ou hiperglicemia como doença, método para tratamento ou controle de distúrbios lipìdicos, hiperlipidemia, ou baixo nìvel de hdl em um paciente mamìfero necessitado do mesmo, método para tratamento ou controle de hipercolesterolemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de hipergligeridemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de dislipidemia e/ou baixo nìvel de hdl colesterol em um paciente mamìfero necessitado de um tal tratamento, e método para tratamento de arteriosclerose em um paciente mamìfero necessitado de um tal tratamento
NO20084792L (no) Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer
Ashamalla et al. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy
Bai et al. Suxiao jiuxin pill induces potent relaxation and inhibition on contraction in human artery and the mechanism
CR8850A (es) Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales
BRPI0512869A (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
NO20064964L (no) Behandling av svekket respiratorisk funksjon
PE20040924A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
EP2166852A4 (en) THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES
Dick et al. Organic and psychogenic causes of sexual dysfunction in young men

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application